<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04222257</url>
  </required_header>
  <id_info>
    <org_study_id>SATIE</org_study_id>
    <nct_id>NCT04222257</nct_id>
  </id_info>
  <brief_title>Short-course Antibiotic Treatment in Gram-positive Cocci Infective Endocarditis</brief_title>
  <acronym>SATIE</acronym>
  <official_title>Short-course Antibiotic Regimen Compared to Conventional Antibiotic Treatment for Gram-positive Cocci Infective Endocarditis: Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Carmen Olmos Blanco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital San Carlos, Madrid</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: it is well known that most serious complications of infective endocarditis (IE)
      appear in the so-called &quot;critical phase&quot; of the disease, which are the first days after
      diagnosis. Subsequently, the vast majority of patients who overcome this acute phase has a
      favourable evolution, and usually stay in the hospital for a long time only to complete
      antibiotic therapy.

      In stable patients with adequate response to antibiotic treatment, without signs of
      persistent infection or metastatic foci such as spondylodiscitis, it is likely that a shorter
      antibiotic regimen would be an efficient and safe alternative, as has already been confirmed
      in patients with IE on tricuspid valves caused by a microorganism considered virulent such as
      S. aureus. This attractive alternative would improve patients' quality of life, save costs,
      and decrease the risk of complications related to the adverse effects of prolonged antibiotic
      treatment.

      Objectives: to compare the incidence of the composite endpoint of all-cause mortality,
      unplanned cardiac surgery, symptomatic embolisms and relapses within 6 months after the
      inclusion between patients with IE caused by gram-positive cocci receiving a short-course of
      2 weeks of antibiotic therapy and those patients receiving conventional antibiotic therapy
      (4-6 weeks).

      Methodology: multicenter, prospective, randomized, controlled open-label, phase IV clinical
      trial. Sample: patients with IE caused by gram-positive cocci, having received at least 10
      days of conventional antibiotic treatment, and at least 7 days after surgery when indicated,
      without clinical, analytical, microbiological or echocardiographic signs of persistent
      infection. Estimated sample size: 298 patients. Intervention: Control group: standard
      antibiotic therapy, according to ESC guidelines recommendations, for 4 to 6 weeks.
      Experimental group: short-course antibiotic therapy for 2 weeks. The prevalence of previously
      known risk factors for adverse events will be compared between the two groups to confirm that
      randomization have worked properly. The incidence of the composite endpoint of all-cause
      mortality, unplanned cardiac surgery, symptomatic embolisms and relapses within 6 months
      after the inclusion in the study will be prospectively registered and compared.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2020</start_date>
  <completion_date type="Anticipated">March 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite endopoint</measure>
    <time_frame>6 months</time_frame>
    <description>To compare the incidence of the composite endpoint that includes all-cause mortality, unplanned cardiac surgery, symptomatic embolisms and relapses within 6 months after the inclusion, between patients with IE caused by gram-positive cocci receiving a short course of 2 weeks of antibiotic therapy and those patients receiving conventional antibiotic therapy for 4-6 weeks.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Perceived quality of life: SF-12</measure>
    <time_frame>4 weeks</time_frame>
    <description>Determination of quality of life (SF-12)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional performance</measure>
    <time_frame>4 weeks</time_frame>
    <description>Determination of functional performance according to the short performance physical battery test (SPPB)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical complications</measure>
    <time_frame>6 months</time_frame>
    <description>Clinical complications related to hospital stay (nosocomial infections, intravascular catheter-related infections)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total hospital length of stay</measure>
    <time_frame>6 months</time_frame>
    <description>Total hospital length of stay in the next 6 months after the inclusion in the study</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">298</enrollment>
  <condition>Endocarditis, Bacterial</condition>
  <arm_group>
    <arm_group_label>Short course</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients allocated to this group will receive a short course of antibiotic therapy for 2 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard course</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Those patients allocated to continue with standard parenteral treatment will maintain the same antibiotic treatment for 4 to 6 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antibiotics</intervention_name>
    <description>Patients allocated to this group will receive a short course of antibiotic therapy for 2 weeks.</description>
    <arm_group_label>Short course</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antibiotics</intervention_name>
    <description>Patients allocated to continue with standard parenteral treatment will maintain the same antibiotic treatment for 4 to 6 weeks.</description>
    <arm_group_label>Standard course</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Definite IE, according to modified ESC 2015 criteria, caused by gram-positive cocci
             (staphylococci, streptococci and enterococci), including native, prosthetic valve IE
             and cardiac device-related IE.

          -  18 years old or older.

          -  Patients treated for at least 10 days of appropriate parenteral antibiotic therapy
             overall (according to guidelines and microbiology sensitivity testing), and at least 7
             days of parenteral antibiotic therapy after valve surgery when indicated.

          -  Absence of fever, microbiological or analytical findings suggesting persistent
             infection at randomization.

          -  Absence of locally uncontrolled infection signs (abscess, pseudoaneurysm, fistula,
             enlarging vegetation) at randomization, confirmed by recent transesophageal
             echocardiography (performed within 48 h of randomization).

          -  Women of childbearing potential who will agree to the use of effective contraceptive
             methods while on antibiotic treatment.

        Exclusion Criteria:

          -  Patients who have received appropriate parenteral antibiotic therapy for infective
             endocarditis for more than 12 days.

          -  Patients not suitable to be discharged after 10 days of conventional treatment, due to
             clinical reasons (sequels of stroke that prevent discharge, progressive renal failure,
             hepatic failure).

          -  Patients receiving chemotherapy or immunosuppressive therapy.

          -  Pregnant or breastfeeding women.

          -  Need of prolonged antibiotic therapy due to spondylodiscitis or other septic
             complication.

          -  Absence of patient's ability or commitment to continue follow-up after being
             discharged from hospital.

          -  Inability to give informed consent to participation.

          -  Cognitive impairment or lack of language skills needed to complete the questionnaires.

          -  Patients who meet urgent cardiac surgery ESC criteria but are considered inoperable
             due to high surgical risk.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Carmen Olmos Blanco, MD</last_name>
    <phone>+0034-913303149</phone>
    <email>carmen.olmosblanco@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cardiovascular Institute. Hospital Cl√≠nico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Carmen Olmos Blanco</last_name>
      <phone>+0034-913303149</phone>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>December 19, 2019</study_first_submitted>
  <study_first_submitted_qc>January 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 9, 2020</study_first_posted>
  <last_update_submitted>January 7, 2020</last_update_submitted>
  <last_update_submitted_qc>January 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hospital San Carlos, Madrid</investigator_affiliation>
    <investigator_full_name>Carmen Olmos Blanco</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>Infective endocarditis</keyword>
  <keyword>short-course</keyword>
  <keyword>antibiotic therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endocarditis, Bacterial</mesh_term>
    <mesh_term>Endocarditis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

